CD70-targeting NK cell therapy for blood cancer relapse
Treatments studied
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This study tests an immune therapy made from cord blood “NK cells” that are engineered to attack cells with a marker called CD70. It’s given after chemotherapy that reduces your blood and immune system, aiming to treat relapse or refractory (not responding) blood cancers.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your tumor sample must show CD70 in at least 10% of cells (checked with biopsy test).
- You must be at least 12 years old and weigh at least 40 kg.
- You must have had chemotherapy at least 1 week before the study’s chemotherapy starts (with limited exceptions).
- Your overall health must be good enough (heart, lungs, liver, kidneys) for treatment.
- You must be able to sign consent and agree to long-term follow-up.
- You must use reliable birth control during the study and for about 3 months after, if you can get pregnant or father a child.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new type of cell therapy called CAR NK cells that are designed to find and attack lymphoma cells carrying a marker called CD70. It is for people whose lymphoma either did not go away after the first treatment or came back within a year.
This trial tests a new type of immune cell therapy using cord blood cells that are grown to attack cancer cells. It is for people with certain blood cancers (lymphoma or acute lymphoblastic leukemia) that have come back or not responded to standard treatments.
This trial tests a customized immune-cell treatment (CAR T) that targets CD70 on cancer cells in certain blood cancers. It may help people whose disease has returned or did not respond to standard treatments.
This trial tests a new kind of immune cell therapy (NK cells) that are made to attack cancer cells carrying the CD5 marker. You will have a short course of chemotherapy before the infusion to help the cells work. It is for people with certain blood cancers that have not responded to standard treatments.
This trial tests a new treatment made from your own immune cells, called CAR T cells, that are designed to find and attack leukemia cells with a specific marker called CD70. It may be an option if your leukemia has come back or not responded to standard treatments and you might be able to receive a stem cell transplant if this treatment helps.
This trial tests a customized immune-cell treatment (NK cells) for certain blood cancers to try to control or eliminate cancer cells. You may qualify if your cancer has come back, did not fully respond, or has higher risk features.
Hear when a new Lymphoma, B-Cell trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.